Aclaris Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Aclaris Therapeutics

03/11/2023 18:09

* Aclaris Therapeutics Inc  ACRS.OQ   ACRS.O  is expected
to show
a fall in quarterly revenue when it reports  results 
    * The Wayne Pennsylvania-based  company is expected to
report  a
91.7% decrease in revenue to $1.574 million from $19.02 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Aclaris
Therapeutics Inc
is for a loss of 48 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aclaris
Therapeutics Inc is $29.5​, above​ its last closing price
of $5.07. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.44       -0.45      -0.42     Beat    6.7
 Mar. 31 2023  -0.43       -0.44      -0.40     Beat    8.6
 Dec. 31 2022  -0.45       -0.45      -0.41     Beat    8​
 Sep. 30 2022  -0.39       -0.40      -0.30     Beat    24.2
 ​​Jun.        -0.36       -0.36      -0.31     Beat    13.5
 30 2022                                                
 Mar. 31 2022  -0.40       -0.40      -0.31     Beat    23.1​
 Dec. 31 2021  -0.37       -0.36      -0.37     Missed  -1.4
 Sep. 30 2021  -0.29       -0.28      -0.35     Missed  -25
 This summary was machine generated November 3 at 18:08 GMT.  All
figures in US dollars  unless otherwise stated